PDSB - PDS Biotechnology Corp (PDSB) - Conference Call Clarifies Data and Mechanism of PDS0101

PDS Held A Conference Call Following ASCO Data Presentations. On June 7, PDS management held a conference call to discuss the full data from its presentations at the American Society for Clinical Oncology (ASCO) meeting on June 5 and 6. The presentations were from the Phase 2 VERSATILE-002 trial testing PDS0101 in head and neck cancer and the Phase 2 Triple Combination trial testing PDS0101 with two immune modulating drugs in multiple tumor types.Two Trials Presented Data At ASCO. PDS0101 was developed using the PDS Versamune technology to stimulate an immune response to HPV16, an immune marker found on human papilloma virus (HPV) related cancers. The VERSATILE-002 trial tested PDS0101 the combination with Merck's pembrolizumab (Keytruda), using the checkpoint inhibitor to make the tumor recognizable to the immune system along with PDS0101 to improve the immune response and kill the tumor cells. Read More >>